[Skip to Content]
[Skip to Content Landing]
October 25, 1985

Reviewing new, very complicated drugs

JAMA. 1985;254(16):2215-2216. doi:10.1001/jama.1985.03360160043007

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


"Fda is one of the few federal government organizations that everybody knows," says Harry M. Meyer, Jr, MD, director of the Center for Drugs and Biologics, "and according to a Roper Poll conducted in August 1984, 78% of the public has a favorable opinion of us. Among 15 widely recognized federal agencies, we're second only to the National Park Service in terms of positive public image."

That evaluation is clearly pleasing to this Public Health Service physician, who has been involved with federal control of pharmaceutical products since 1959. Meyer, who is a pediatrician, started his government service as a research virologist with the Division of Biologics Standards, then part of the National Institutes of Health (NIH) in Bethesda, Md. In 1972, when the division became part of the FDA, he left the laboratory to become head of what was called the Bureau of Biologics.

When a decision was made